Atlas Trials

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Clinical trial NCT06346392 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06346392
Sponsor
AstraZeneca
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Gastric CancerGastroesophageal Junction Cancer
Start date
2024-03-04
Primary completion
2026-05-31
Enrollment
594

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.